CTLA4 and cancer: The emergence of immunotherapy has shed light on cancer therapy; TMB and immune checkpoints, such as PD-L1, CTLA-4, LAG3, TIM3, and TIGIT, act as gatekeepers or biomarkers of immune responses (Kim et al., 2019; He and Xu, 2020).